Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline Review, H2 2016’, provides an overview of the Clostridium difficile Infections (Clostridium difficile Associated Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Clostridium difficile Associated Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Clostridium difficile Associated Disease)

The report reviews pipeline therapeutics for Clostridium difficile Infections (Clostridium difficile Associated Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Clostridium difficile Infections (Clostridium difficile Associated Disease) therapeutics and enlists all their major and minor projects

The report assesses Clostridium difficile Infections (Clostridium difficile Associated Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Clostridium difficile Associated Disease)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Clostridium difficile Infections (Clostridium difficile Associated Disease)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Clostridium difficile Infections (Clostridium difficile Associated Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Absynth Biologics Limited

Actelion Ltd

Adenium Biotech ApS

AIMM Therapeutics B.V.

Akthelia Pharmaceuticals Limited

AmpliPhi Biosciences Corporation

Angothera GmbH

Antibiotx ApS

Appili Therapeutics Inc

Assembly Biosciences Inc

AvidBiotics Corp.

C3 Jian, Inc

CaroGen Corporation

Crestone, Inc.

Da Volterra

Daiichi Sankyo Company, Limited

e-Therapeutics Plc

Evec, Inc.

GangaGen Inc.

ImmunoBiology Limited

Immuron Limited

Inovio Pharmaceuticals, Inc.

Integrated BioTherapeutics, Inc.

MedImmune, LLC

Merck & Co., Inc.

MGB Biopharma Limited

Microbiotix, Inc.

Micropharm Limited

Miyarisan Pharmaceutical Company, Ltd

Morphochem AG

Nanotherapeutics, Inc.

Novabiotics Limited

NovoBiotic Pharmaceuticals, LLC

Oragenics, Inc.

Otsuka Holdings Co., Ltd.

Pfizer Inc.

Procarta Biosystems Limited

Prokarium Limited

Rebiotix Inc.

Sanofi Pasteur SA

Second Genome, Inc.

Seres Therapeutics, Inc.

Sorrento Therapeutics, Inc.

Stellar Biotechnologies, Inc.

Summit Therapeutics Plc

Synthetic Biologics, Inc.

Valevia UK Limited

Valneva SE

Venenum Biodesign, L.L.C

XBiotech Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Clostridium difficile Infections (Clostridium difficile Associated Disease) Overview 7

Therapeutics Development 8

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics under Development by Companies 10

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics under Investigation by Universities/Institutes 13

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Products Glance 14

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Products under Development by Companies 18

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Products under Investigation by Universities/Institutes 23

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development 24

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment 74

Drug Profiles 84

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects 194

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products 197

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones 198

Appendix 208

List of Tables

List of Tables

Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H2 2016 17

Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease) – Comparative Analysis, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Number of Products under Development by Companies, H2 2016 (Contd..1) 20

Number of Products under Development by Companies, H2 2016 (Contd..2) 21

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Comparative Analysis by Late Stage Development, H2 2016 23

Comparative Analysis by Clinical Stage Development, H2 2016 24

Comparative Analysis by Early Stage Development, H2 2016 25

Comparative Analysis by Unknown Stage Development, H2 2016 26

Products under Development by Companies, H2 2016 27

Products under Development by Companies, H2 2016 (Contd..1) 28

Products under Development by Companies, H2 2016 (Contd..2) 29

Products under Development by Companies, H2 2016 (Contd..3) 30

Products under Development by Companies, H2 2016 (Contd..4) 31

Products under Investigation by Universities/Institutes, H2 2016 32

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Absynth Biologics Limited, H2 2016 33

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Actelion Ltd, H2 2016 34

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Adenium Biotech ApS, H2 2016 35

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by AIMM Therapeutics B.V., H2 2016 36

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Akthelia Pharmaceuticals Limited, H2 2016 37

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by AmpliPhi Biosciences Corporation, H2 2016 38

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Angothera GmbH, H2 2016 39

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Antibiotx ApS, H2 2016 40

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Appili Therapeutics Inc, H2 2016 41

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Assembly Biosciences Inc, H2 2016 42

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by AvidBiotics Corp., H2 2016 43

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by C3 Jian, Inc, H2 2016 44

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by CaroGen Corporation, H2 2016 45

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Crestone, Inc., H2 2016 46

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Da Volterra, H2 2016 47

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 48

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by e-Therapeutics Plc, H2 2016 49

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Evec, Inc., H2 2016 50

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by GangaGen Inc., H2 2016 51

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by ImmunoBiology Limited, H2 2016 52

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Immuron Limited, H2 2016 53

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 54

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Integrated BioTherapeutics, Inc., H2 2016 55

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by MedImmune, LLC, H2 2016 56

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Merck & Co., Inc., H2 2016 57

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by MGB Biopharma Limited, H2 2016 58

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Microbiotix, Inc., H2 2016 59

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Micropharm Limited, H2 2016 60

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Miyarisan Pharmaceutical Company, Ltd, H2 2016 61

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Morphochem AG, H2 2016 62

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Nanotherapeutics, Inc., H2 2016 63

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Novabiotics Limited, H2 2016 64

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2016 65

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Oragenics, Inc., H2 2016 66

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Otsuka Holdings Co., Ltd., H2 2016 67

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Pfizer Inc., H2 2016 68

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Procarta Biosystems Limited, H2 2016 69

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Prokarium Limited, H2 2016 70

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Rebiotix Inc., H2 2016 71

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Sanofi Pasteur SA, H2 2016 72

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Second Genome, Inc., H2 2016 73

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Seres Therapeutics, Inc., H2 2016 74

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Sorrento Therapeutics, Inc., H2 2016 75

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Stellar Biotechnologies, Inc., H2 2016 76

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Summit Therapeutics Plc, H2 2016 77

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Synthetic Biologics, Inc., H2 2016 78

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Valevia UK Limited, H2 2016 79

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Valneva SE, H2 2016 80

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Venenum Biodesign, L.L.C, H2 2016 81

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Pipeline by XBiotech Inc, H2 2016 82

Assessment by Monotherapy Products, H2 2016 83

Assessment by Combination Products, H2 2016 84

Number of Products by Stage and Target, H2 2016 86

Number of Products by Stage and Mechanism of Action, H2 2016 88

Number of Products by Stage and Route of Administration, H2 2016 90

Number of Products by Stage and Molecule Type, H2 2016 92

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects, H2 2016 203

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects (Contd..1), H2 2016 204

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Dormant Projects (Contd..2), H2 2016 205

Clostridium difficile Infections (Clostridium difficile Associated Disease) – Discontinued Products, H2 2016 206

List of Figures

List of Figures

Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H2 2016 17

Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease) – Comparative Analysis, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Comparative Analysis by Late Stage Development, H2 2016 23

Comparative Analysis by Clinical Stage Development, H2 2016 24

Comparative Analysis by Early Stage Products, H2 2016 25

Assessment by Monotherapy Products, H2 2016 83

Number of Products by Top 10 Targets, H2 2016 85

Number of Products by Stage and Top 10 Targets, H2 2016 85

Number of Products by Top 10 Mechanism of Actions, H2 2016 87

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 87

Number of Products by Routes of Administration, H2 2016 89

Number of Products by Stage and Routes of Administration, H2 2016 89

Number of Products by Top 10 Molecule Types, H2 2016 91

Number of Products by Stage and Top 10 Molecule Types, H2 2016 91

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports